vinit sambre

Despite being a defensive bet, pharmaceutical stocks have languished in 2022 primarily because of challenges like the poor pricing environment in the US, cross-currency fluctuations,…
Read More...

“Just stay invested and try to go through the volatility phase which I believe one will have to live with over the next few months,” says Vinit Sambre, Head-Equities, DSP Mutual Fund…
Read More...